HIV PrEP CAN'T WAIT
HIV PrEP CAN'T WAIT: Implementing long-acting HIV prevention in the Prairies and across Canada
Long-acting HIV pre-exposure prophylaxis (PrEP) offers an alternative to daily pills, but services need to know how to offer it well and to whom. HIV PrEP CAN'T WAIT is an umbrella study whose first stage prepares sites in the Prairies and across Canada for implementation.
Map how HIV prevention services currently work at participating sites.
Identify what providers and clients need for long-acting PrEP modalities to be offered and taken up.
Define the implementation strategies, choice interventions and supports to be tested in the later implementation trials.
Stage 1, led by the RISE³ Lab, is underway: process mapping, focus groups with sites, and interviews with providers and clients. In the lab, the work is carried out by postdoctoral fellow Dr. Omolara Akingba. Gilead Sciences funds this pre-implementation research; ViiV Healthcare funds the implementation trials of long-acting PrEP modalities, with choice interventions and supports, that will follow once Stage 1 is complete.
Stage 1 uses the same pre-implementation methods as SCALE-POCT: process mapping, focus groups with sites, and interviews with providers and clients, guided by implementation science frameworks. The ViiV-funded second stage will implement and evaluate long-acting PrEP modalities with different choice interventions and supports.
- Process maps and determinant analyses for participating sites
- A set of implementation strategies and supports ready for the Stage 2 implementation trials
Co-led with Dr. Marina Klein (McGill University), Dr. Zoe Moody and Dr. Daryl Tan, with participating sites in the Prairies and across Canada.
Enquire about HIV PrEP CAN'T WAIT
Participating sites, collaborations and trainee projects on long-acting HIV prevention.